Pancreatic cancer is a deadly disease, and its most common form, pancreatic ductal adenocarcinoma (PDAC), is a ticking time bomb. But what if a common anesthetic could be the key to slowing its spread? A bold claim, but one that researchers are exploring.
The pancreas, nestled between the stomach and spine, plays a vital role in digestion and blood sugar regulation. Unfortunately, it's also a breeding ground for PDAC, a highly aggressive cancer. PDAC is a silent killer, often going undetected until it's too late. It's the third leading cause of cancer deaths in the U.S., and only 13% of patients survive beyond five years.
Here's where the story takes a fascinating turn: A team of medical professionals and engineers at the University of Illinois Chicago is investigating the impact of lidocaine, a local anesthetic, on pancreatic cancer cells released during surgery. Their groundbreaking research, published in the journal Lab on a Chip, focuses on capturing these rogue cells.
"The potential of lidocaine to mitigate metastasis and improve patient outcomes is truly remarkable," says Dr. Gina Votta-Velis, the lead investigator and a UIC professor of anesthesiology. This statement is intriguing, but could it be too good to be true?
Circulating tumor cells (CTCs) are the culprits behind cancer's spread. These cells break away from the tumor during surgery and escape into the bloodstream, leading to higher recurrence rates and poorer prognoses. But Votta-Velis and her team believe lidocaine might just be the hero we need. And this is the part most people miss: preliminary studies suggest that lidocaine can trap these CTCs within the bloodstream, preventing them from forming new tumors, and allowing our immune system to clean them up naturally.
However, isolating CTCs is no easy task. It's like finding a needle in a haystack, as these cells are rare in the bloodstream. Enter Ian Papautsky, a fellow researcher at the University of Illinois Cancer Center and a professor of biomedical engineering. Papautsky specializes in microfluidics, the study of how tiny amounts of fluids flow through minuscule channels. His innovation is a small device that isolates cancer cells from blood samples based on their size, a process known as a liquid biopsy.
"Cancer cells have unique characteristics that we can exploit," explains Papautsky. "They are larger and softer than other blood cells. Our device filters out these CTCs without harming them." In a 2019 study, Papautsky's method proved highly accurate, capturing cancer cells with 93% precision. When compared to a commercial tool called EasySep, which uses magnetic separation, Papautsky's approach was gentler and more effective, recovering eight times as many cancer cells and processing samples faster.
This discovery is a significant step forward, especially for cancers like PDAC, where early diagnosis is challenging. Dr. Pier Giulianotti, a co-investigator and surgical expert, emphasizes the importance of understanding how cancer cells spread through the bloodstream and the potential to control this process.
The research team's findings open up exciting possibilities for personalized medicine. But here's where it gets controversial: Could a simple anesthetic really be a game-changer in the fight against pancreatic cancer? The study's results are promising, but further research is needed to fully understand the potential of lidocaine. What do you think? Is this a medical breakthrough or a fascinating hypothesis? Share your thoughts in the comments!
